A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults.

Medicine (Baltimore) · 2024 · PMC11688028 · PMID 39969346

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

a nonsignificant trendP = .09so close (0.05 < p ≤ 0.1)

[ 15 – 17 ] A meta-analysis of 4 randomized controlled trials with 1130 patients (816 receiving pridopidine, 314 receiving placebo) found a nonsignificant trend favoring pridopidine in the Unified HD Rating Scale Total Motor Score (mean difference, −0.93; 95% CI, −2.01 to 0.14; P = .09).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.